These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 7581109

  • 1. Peripheral tolerance to host minor histocompatibility antigens in radiation bone marrow chimeras abrogates lethal GVHD while preserving GVL effect.
    de la Selle V, Miconnet I, Gilbert D, Bruley-Rosset M.
    Bone Marrow Transplant; 1995 Jul; 16(1):111-8. PubMed ID: 7581109
    [Abstract] [Full Text] [Related]

  • 2. CD8+ cytotoxic T cell repertoire implicated in grafts-versus-leukemia effect in a murine bone marrow transplantation model.
    de La Selle V, Riché N, Dorothé G, Bruley-Rosset M.
    Bone Marrow Transplant; 1999 May; 23(9):951-8. PubMed ID: 10338053
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Mls-1a-induced peripheral tolerance to host minor histocompatibility antigens in radiation bone marrow chimeras. Modification of T cell repertoire associated with active suppression and permanent presentation of host antigens.
    Miconnet I, Bruley-Rosset M, Halle-Pannenko O.
    J Immunol; 1992 Jun 15; 148(12):3706-13. PubMed ID: 1534822
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Graft-versus-leukemia effect using mixed allogeneic bone marrow transplantation.
    Sykes M, Bukhari Z, Sachs DH.
    Bone Marrow Transplant; 1989 Sep 15; 4(5):465-74. PubMed ID: 2790325
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. An MHC-compatible allogeneic bone marrow donor with a distinct role of T cell subsets in graft-versus-leukemia effect and lethal graft-versus-host disease.
    Aizawa S, Kamisaku H, Sado T.
    Bone Marrow Transplant; 1995 Oct 15; 16(4):603-9. PubMed ID: 8528179
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
    Xia G, Truitt RL, Johnson BD.
    Biol Blood Marrow Transplant; 2006 Apr 15; 12(4):397-407. PubMed ID: 16545723
    [Abstract] [Full Text] [Related]

  • 13. Allospecific CD8+ Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease.
    Fowler DH, Breglio J, Nagel G, Eckhaus MA, Gress RE.
    J Immunol; 1996 Dec 01; 157(11):4811-21. PubMed ID: 8943383
    [Abstract] [Full Text] [Related]

  • 14. A CD8 DE loop peptide analog prevents graft-versus-host disease in a multiple minor histocompatibility antigen-mismatched bone marrow transplantation model.
    Choksi S, Kim JC, Whitaker-Menezes D, Murphy GF, Friedman TM, Korngold R.
    Biol Blood Marrow Transplant; 2004 Oct 01; 10(10):669-80. PubMed ID: 15389433
    [Abstract] [Full Text] [Related]

  • 15. Relative importance of CD4+ and CD8+ T cell repertoires in the development of acute graft-versus-host disease in a murine model of bone marrow transplantation.
    Miconnet I, de La Selle V, Bruley-Rosset M.
    Bone Marrow Transplant; 1998 Mar 01; 21(6):583-90. PubMed ID: 9543062
    [Abstract] [Full Text] [Related]

  • 16. Use of anti-CD3 epsilon F(ab')2 fragments in vivo to modulate graft-versus-host disease without loss of graft-versus-leukemia reactivity after MHC-matched bone marrow transplantation.
    Johnson BD, McCabe C, Hanke CA, Truitt RL.
    J Immunol; 1995 May 15; 154(10):5542-54. PubMed ID: 7730653
    [Abstract] [Full Text] [Related]

  • 17. Immunomonitoring of graft-versus-host minor histocompatibility antigen correlates with graft-versus-host disease and absence of relapse after graft.
    Laurin D, Hannani D, Pernollet M, Moine A, Plumas J, Bensa JC, Cahn JY, Garban F.
    Transfusion; 2010 Feb 15; 50(2):418-28. PubMed ID: 19843288
    [Abstract] [Full Text] [Related]

  • 18. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
    Weiss L, Lubin I, Factorowich I, Lapidot Z, Reich S, Reisner Y, Slavin S.
    J Immunol; 1994 Sep 15; 153(6):2562-7. PubMed ID: 8077666
    [Abstract] [Full Text] [Related]

  • 19. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy.
    Johnson BD, Becker EE, LaBelle JL, Truitt RL.
    J Immunol; 1999 Dec 15; 163(12):6479-87. PubMed ID: 10586039
    [Abstract] [Full Text] [Related]

  • 20. Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease.
    Anderson LD, Mori S, Mann S, Savary CA, Mullen CA.
    Cancer Res; 2000 Oct 15; 60(20):5797-802. PubMed ID: 11059776
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.